|Bid||7.40 x 1000|
|Ask||7.89 x 1000|
|Day's Range||7.55 - 7.93|
|52 Week Range||2.20 - 9.24|
|Beta (5Y Monthly)||1.95|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 13, 2023 - Nov 17, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.00|
Subscribe to Yahoo Finance Plus to view Fair Value for IMNM
SEATTLE & EXTON, Pa., October 03, 2023--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it has completed its previously announced merger with Morphimmune.
Key Insights Immunome's significant individual investors ownership suggests that the key decisions are influenced by...
EXTON, Pa., August 09, 2023--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics to improve patient care, today reported financial results for the second quarter ended June 30, 2023 and provided a corporate update.